Jagsonpal Pharma delivered robust Q1 FY27 financial results: revenue grew 9% to Rs. 82 Cr, EBITDA rose 21% to Rs. 19 Cr, and PAT increased 22% to Rs. 13 Cr.

Gross margins surpassed 65%. A key strategic move was acquiring an 85% stake in Aequitas Healthcare for Rs. 20.8 Cr, providing immediate access to the hospital segment.

Aequitas, with FY26 revenue of Rs. 53 Cr (EBITDA Rs. 0.5 Cr), targets Rs. 100 Cr revenue and Rs. 10 Cr EBITDA in 2.5 years.

Management is focused on organic growth, brand building, and efficiency, targeting 1.5x industry growth.

Maintane, Indocap, and Endoreg are highlighted as key growth drivers.

Management's outlook is confident.